More funding and another powerful pharma backer have entered the microbiome space, showing that at least some investors and pharma execs believe the field can begin converting preclinical ideas into valid human therapies.
Somerville, Massachusetts-based Finch Therapeutics announced a new agreement with Takeda Pharmaceuticals on Wednesday, a solid endorsement of its sophisticated bioinformatics platform.
Along with oncology and central nervous system disorders, gastrointestinal diseases are one of Takeda’s three therapeutic pillars. As part of the deal, Takeda will pay an upfront $10 million for exclusive worldwide rights to FIN-524, an investigational drug for ulcerative colitis, and any follow-on products for irritable bowel diseases (IBDs). Ulcerative colitis is a form of IBD in which the immune system attacks the lining of the large intestine.
Finch’s science taps into the high-potential, highly-unpalatable concept of a fecal transplant. It involves transferring a microbiota rich stool sample from a healthy individual into someone with severe gut dysbiosis.
It’s a smart approach, given how little we know about the many thousands of microbial strains that occupy our guts. Instead of adding them to a therapy one-by-one, scientists can take a sample ecosystem that is already known to work. Finch then has a feedback loop in place to determine how patients responded to the different donor cultures.
“By working from clinically annotated datasets of donor and patient microbiota before and after fecal transplantation, we can look for the patterns in changes to the patients’ microbiota associated with targeted clinical outcomes,” said Finch CEO Mark Smith in an email forwarded by a company representative.
It underscores how variable our microbiomes are, whether we’re healthy, sick, or somewhere in between.
Smith cited a 70-patient randomized control trial of fecal transplants performed at McMaster University (Moayyedi et al, 2015). Five donors were used in the study, but just one, Donor B, had a demonstrably large therapeutic effect. Without Donor B, the study would have failed.
Just how much Kombucha was Donor B drinking? And how do we learn from the strength of that participant’s microbiota? Finch is working to answer the latter.
While gut bacteria and the microbiome are often used interchangeably, our microscopic citizens really populate our entire body, including the skin. That’s the target for Farmington, Connecticut-based Azitra.
Azitra announced on Wednesday that it had closed a $2.9 million Series A venture round led by Bios Partners. With earlier seed funding, including from Peter Thiel’s Breakout Labs program, the startup has raised $3.75 million to date.
Rather than brewing a complex bacterial concoction, Azitra has identified one key bacteria strain for its lead candidate, AZT-01, to be applied as a cream to affected skin. In its cross-hairs for treatment are eczema, rare genetic skin diseases, and more everyday cosmetic applications such as dry skin.
In an email forwarded by a company representative, Azitra Cofounder and CSO Travis Whitfill said the microbial treatment isn’t just a band-aid — it could address an underlying cause.
“Studies have repeatedly shown that these patients have an imbalanced microbiome, and in the case of eczema, they often have an overgrowth of Staph aureus. There is also evidence that our strain of bacteria can kill some strains of Staph aureus, which is one of the reasons we chose it as a chassis,” Whitfill said.
Applied topically, the good bacteria can colonize the area and begin correcting the dysbiosis.
Photo: spawns, Getty Images
Redox Engine, the Madison, Wisconsin health IT startup that’s helping healthcare facilities overcome interoperability challenges has received $1 million in follow-on investment from Intermountain Healthcare Innovation Fund, according to a company release. The funding is part of Redox’s Series B round.
Redox will work with Intermountain in the Salt Lake City-based health system’s push to adopt digital health solutions that fit into their electronic health record. The company will also support applications Intermountain has developed, such as the Rehab Outcomes Management System, as part of Redox’s API platform.
Healthbox has previously run an accelerator for healthcare startups called Healthbox Studio but with the management change last year, Healthbox repositioned itself as a venture capital investment manager with an innovation platform that functions as a consultant to and collaborator with healthcare partners.
Healthbox has managed Intermountain Healthcare’s Innovation Fund since the fund’s launch in 2015. The fund is intended to source, evaluate, and invest in companies that align with Intermountain’s mission. So far the fund has made a handful of investments in healthcare startups, in addition to Redox:
Zebra Medical Vision, an Israel-based health IT business, developed a clinical decision support teaching computers to read and diagnose medical images through machine learning. Last year, Zebra closed a Series B round as it launched a consumer-facing product called Profound. The service allows individuals to upload their medical imaging scans such as computerized tomography scans and mammograms to Zebra Medical Vision’s online service, and receive an automated analysis of key clinical conditions.
Syapse is a precision medicine software meets clinical decision support startup. It seeks to improve care coordination for hospitals by extracting clinical, genomic and other molecular data from medical records, labs and pharmacies and integrating that data to offer more detailed patient profiles. By doing this, the company wants to guide doctors to find the right diagnostic test and therapeutic approach. The Intermountain fund took part in its Series C round.
Photo: jpa1999, Getty Images
News from Twitter
Congratulations to Rory Sabbatini, prodisc® athlete-ambassador, on his 6th place finish at the @CSChallengeFW. Rory and @BrianGayPGA played the green well this weekend—while educating @PGATOUR fans on spinal surgery with prodisc. bit.ly/2W9cUSb #regainyourlife
I am lucky to work for a company that gives a person the ability to want to make every day count. TranS1 has given me the ability to stop looking back and remember how to live a life - Get back to living! #tuesdayteammember #T14life #lovewhereyouwork #lovewhatyoudo pic.twitter.com/IiCV…
Nous profitons de la #JournéeMondialeContreLHypertension pour vous rappeler que notre mission est de développer de nouvelles thérapies innovantes pour les besoins médicaux non satisfaits dans le domaine des maladies cardiovasculaires. #Hypertension #Firibastat #QuantumGenomics pic.twitter.com/bELl…
We are saddened to share the news of the passing of Dr. Yves Cotrel. A pioneer in modern spine surgery, Dr. Cotrel's company Sofamor, was the foundation for what would become Medtronic Spine. Dr. Cotrel's contributions will live on for years to come. Condolences to his family. pic.twitter.com/JJ1Z…
The 44th edition of Arab Health is officially now open. #ArabHealth2019 runs until the 31st of January 2019 at the Dubai World Trade Centre and the Conrad Dubai from 10 am to 6 pm. Find out more on our website or download the Arab Health 2019 show app: bit.ly/2n3Z5Q pic.twitter.com/oasI…
Cancer is not a ‘one size fits all,’ nor is the way we treat it. We are working to better understand the different ways a cancer can mutate so we can discover new approaches to treat some of the most difficult-to-treat types of the disease. #ReimagineMedicine #ESMO18 pic.twitter.com/41QL…
Large-vessel giant cell arteritis: diagnosis, monitoring and management | Rheumatology | Oxford Academic academic.oup.com/rhe…
Scientists have made an unexpected discovery while investigating the triggering factors of #ColonCancer: Cell stress in combination with an altered microbiota in the colon drives tumor growth. Learn more: ow.ly/JxtK30meLTY pic.twitter.com/U51Q…
If you are in Dallas attending the AAFPRS 12th International Symposium of Facial Plastic Surgery don’t miss out on this Breakfast Symposium tomorrow morning with Dr. William Binder that is sponsored by Implantech! #implantech #superiorpatientaesthetics #implantechrewards #aafprs pic.twitter.com/HCzK…
With #CARTcell therapy, an inactive virus programs T cells with new genetic information to help recognize specific antigens found on normal cells and certain blood cancer cells. As the CAR-T cells multiply, new copies also gain this ability. #CARTCellStory pic.twitter.com/Xuoh…
Make plans to visit the Integra LifeSciences Booth# 919 during Plastic Surgery The Meeting September 28th - October 1st. #Integra_LifeSciences #DurableIsBeautiful #PSTM18 #ASPS #PlasticSurgery pic.twitter.com/8QGv…
We are live at #NASS2018 stand 2649. Get hands-on with the world's leading surgical #simulator in #VR with #haptics and experience the future of surgical training. #wearefundamental fundamentalsurgery.c… pic.twitter.com/NgzA…
Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News